Genmab — Maj 2016
-
Daratumumab ikke noget http://abstracts.asco.org/176/AbstView_176_172609.html alt skal holdes hemmeligt
-
Pressemeddelelse fra Genmab om præsentation på EHA. https://www.nordnet.dk/mux/web/analys/nyheter/visaNyhet.html?itemid=288167007&sourcecode=omxnews
-
Tak Anette.
-
89...Jeg prøver at passe det ind i kalenderen.
-
-
Ofatumumab: 49 (98%) achieved complete remission (CR) after 1 cycle; 92% became negative for minimal residual disease (MRD). The 2-year CR duration and overall survival rates were 74% and 83%, respectively. Conclusions: The combination of ofatumumab with hyper-CVAD is safe and highly effective in pts with CD20+ Ph- ALL.
-
-
Er der mere krudt i Genmab? http://play.borsen.dk/social/573dcd6c725ed7540a0d4fc3
-
Nu vil de negative snart begynde at snakke om gap-luk
-
Novod har ikke korrigeret sit kursmål på 1100! Men hans Darzalex bull-case scenarie indeholder peak-sales på USD 10 milliarder, og kursmål på 1500 eller mere. Samtidig har han peak-sales på Revlimid på 10-14 milliarder USD. Nogen der har et bud på hvorfor peak-sales for Revlimid skulle blive højere end Darzalex? Darzalex er jo det bedste findes indenfor MM.
-
Kan det være fordi Revlimid er dyrere end Darzalex, eller fordi Revlimid kan bruges i flere indikationer?
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind